Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 73Tumor-Agnostic 6Gastrointestinal 6CNS 5Head & Neck 3Genitourinary 3Thoracic 2Gynecologic 2Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Neoplasm Metastasis 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lapatinib × Thoracic × Clear all
NCT00528281 2017-11-17

A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase

GlaxoSmithKline

Phase 1 Completed
18 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00073008 2017-02-28

A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

GlaxoSmithKline

Phase 2 Terminated
131 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡